Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 8.69M | 4.09M | 2.05M | 1.55M | 674.00K |
Gross Profit | 2.75M | 619.00K | 256.00K | 9.00K | -291.00K |
EBITDA | -3.55M | -2.73M | -3.11M | -2.20M | -2.20M |
Net Income | -3.28M | -3.16M | -6.14M | -6.31M | -2.28M |
Balance Sheet | |||||
Total Assets | 10.98M | 9.96M | 10.36M | 16.98M | 2.26M |
Cash, Cash Equivalents and Short-Term Investments | 1.81M | 2.70M | 6.61M | 13.35M | 32.00K |
Total Debt | 2.83M | 2.80M | 2.08M | 4.26M | 1.28M |
Total Liabilities | 4.90M | 4.79M | 2.72M | 4.90M | 2.19M |
Stockholders Equity | 5.75M | 4.70M | 7.64M | 12.09M | 71.00K |
Cash Flow | |||||
Free Cash Flow | -4.31M | -3.93M | -3.09M | -3.02M | -2.11M |
Operating Cash Flow | -3.87M | -3.24M | -2.99M | -2.75M | -1.80M |
Investing Cash Flow | -775.00K | 4.46M | -5.59M | -269.00K | -312.00K |
Financing Cash Flow | 3.75M | 379.00K | -3.66M | 16.34M | 1.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $32.86M | 39.74 | 9.17% | ― | 10.34% | ― | |
56 Neutral | $29.08M | ― | -62.82% | ― | 115.94% | 17.42% | |
53 Neutral | $22.33M | ― | -138.80% | ― | -14.41% | -549.88% | |
52 Neutral | $21.85M | ― | -25.89% | ― | -16.05% | -195.28% | |
51 Neutral | $7.39B | 0.36 | -62.86% | 2.37% | 15.48% | -2.68% | |
43 Neutral | $31.51M | ― | -239.87% | ― | 61.97% | -6.89% |
On July 31, 2025, NEXGEL, Inc. appointed Steven A. Ciardiello to its board of directors and as a member of the Audit Committee. Ciardiello, who is the Chief Accounting Officer for Shutterstock, brings over 25 years of financial leadership experience to NEXGEL. His appointment is seen as a strategic move to enhance the company’s financial governance and support its growth phase. Ciardiello was granted an option to purchase up to 30,000 shares of NEXGEL’s common stock, with vesting conditions tied to his continuous service. This appointment is expected to bolster NEXGEL’s strategic execution and corporate governance, potentially impacting its market positioning positively.
The most recent analyst rating on (NXGL) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on NexGel Inc stock, see the NXGL Stock Forecast page.
On July 31, 2025, NEXGEL, Inc. entered into subscription agreements to sell 413,044 shares of common stock at $2.30 per share in a registered direct offering and issued unregistered warrants to purchase 206,522 shares at $4.25 per share in a concurrent private placement. The transactions are expected to generate approximately $950,000 in gross proceeds before expenses, with the offerings anticipated to close by August 5, 2025. This financing, along with a recent $1 million non-dilutive advance from STADA, is set to strengthen NEXGEL’s balance sheet and provide additional working capital as the company anticipates high growth in the latter half of the year.
The most recent analyst rating on (NXGL) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on NexGel Inc stock, see the NXGL Stock Forecast page.
On July 14, 2025, NEXGEL, Inc. announced the expansion of its partnership with STADA Arzneimittel AG, a European leader in consumer health, to launch digestive enzyme formulas and solutions for scars and stretch marks in North America. As part of the agreement, STADA will provide $1 million in non-dilutive capital to support the product launches and marketing efforts, reflecting a shared vision to bring these health solutions to North American consumers.
The most recent analyst rating on (NXGL) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on NexGel Inc stock, see the NXGL Stock Forecast page.
NexGel, Inc. held its 2025 Annual Meeting of Stockholders on June 17, 2025, where stockholders approved several key proposals. The Fourth Amendment to the 2019 Long-Term Incentive Plan was approved, increasing the authorized common stock by 780,000 shares. Additionally, five directors were elected, executive compensation was approved, and the appointment of Turner, Stone & Company, LLP as the independent registered public accounting firm for 2025 was ratified.
The most recent analyst rating on (NXGL) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on NexGel Inc stock, see the NXGL Stock Forecast page.